INVO2 can Repair Damaged LUNGS, page-22

AC whoever wrote this article  needs to research their subject matter to a higher level.
Quote from article.
"The second asset (INV-104) is a “proposed” inhalable form of leukotriene receptor antagonist (LTRA), zafirlukast. This is an asthma prevention drug that is marketed by AstraZeneca as Accolate, but is now off-patent. I’m not going to spend too much time talking about this asset because it is fundamentally stupid and irrelevant."

This drug was developed under the leadership of our CMO Dr. Mitchell Glass.

"Dr Mitchell Glass, Invion’s Executive Vice President of R&D and Chief Medical Officer, led the development and submission of Accolate for Zeneca (now AstraZeneca) to its FDA approval letter in 1998, and is a substantial shareholder of Accolade Pharma LLC."

"The oral formulation of zafirlukast, currently marketed as a generic drug as well as by AstraZeneca as Accolate, has recently become available in the public domain due to the expiry of its original patents. Accolade Pharma LLC has created a patent strategy and strategic opportunities to develop non-oral formulations of the drug, aimed at reducing side effects and increasing effectiveness"

AstraZeneca tried to formulate an inhaled version but failed.